Frost & Sullivan Applauds the Diversity of Ventana Products and Services for the Cancer Diagnostics Market

Ventana is committed to accelerating the discovery and development of new cancer diagnostic tests that help determine the best course of therapy for each individual patient.


Learn more

See how Ventana Medical Systems, Inc. is shaping the future of healthcare with innovative cancer diagnostic solutions.  

  • Picture1.jpg Ventana Medical Systems, Inc. headquarters in Tucson, Arizona USA

  • Picture2.jpg PD-L1 (SP263) immunohistochemistry assay– (Research Use Only) Positive lung tissue at 20x magnification, stained on a BenchMark ULTRA instrument.

  • Picture3.jpg VENTANA iScan HT: Empowering you to optimize digital pathology with speed, throughput and reliability. (Research Use Only)

Download Photos

Right Click the links below and select "Save As"

Company headquarters

PD-L1 (SP263) immunohistochemistry assay

VENTANA iScan HT


both-logos-eps.gifFrost & Sullivan Applauds the Diversity of Ventana Products and Services for the Cancer Diagnostics Market

Ventana is committed to accelerating the discovery and development of new cancer diagnostic tests that help determine the best course of therapy for each individual patient. 

MOUNTAIN VIEW, Calif. — September 30, 2014 — Based on its recent analysis of the oncology tissue diagnostics market, Frost & Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, with the 2014 North American Frost & Sullivan Award for Technology Innovation Leadership. Adherence to strict quality practices along with a focus on innovation and improving patient safety have made Ventana a global leader in tissue-based cancer diagnostic solutions for patients worldwide.

As a leading supplier of cancer diagnostic systems to the pathology market, Ventana manufactures over 220 cancer tests with related instruments for 90 countries, and most importantly, for the four million people afflicted with cancer each year.  The company is committed to accelerating the discovery and development of new cancer diagnostic tests that allow pathologists to analyze patient samples at the molecular level to help determine the best course of therapy for each individual patient.  

“Ventana’s ability to discover new technology and then develop it into first-ever products aligns with the Blue Ocean Strategy for creating new markets,” noted Frost & Sullivan Research Analyst, Divyaa Ravishankar “For instance, it pioneered automated staining, and was an early leader in the areas of biomarker detection chemistry and companion diagnostics. It is still the only company to provide such a wide portfolio of FDA-approved or cleared assays and algorithms.”

Making the most of Roche’s worldwide infrastructure, which includes significant markets not yet served, Ventana has continued to expand its global install base of automated platforms that run advanced cancer diagnostic tests and has achieved impressive growth for the past five years. Since 2002 Ventana has worked with more than 45 biopharmaceutical partners over the past decade and is currently engaged in more than 180 collaborative projects to develop and commercialize companion diagnostics globally.

Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impact both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend toward innovation, its relevance to the industry and the positive impact on brand perception.

Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research.

About Ventana Medical Systems, Inc.

Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA products are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to help reduce errors, support diagnosis and enable informed treatment decisions by anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies. VENTANA and the VENTANA logo are trademarks of Roche.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation, including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

star_fs_red.pngContact Us: Start the discussion

star_fs_red.pngJoin Us: Join our community

star_fs_red.pngSubscribe: Newsletter on "the next big thing"

star_fs_red.pngRegister: Gain access to visionary innovation

Mireya Espinoza
P: 210. 247.3870
F: 210.348.1003
E: mireya.espinoza@frost.com